[go: up one dir, main page]

NO20035683D0 - Optisk avbildning av prostatakreft - Google Patents

Optisk avbildning av prostatakreft

Info

Publication number
NO20035683D0
NO20035683D0 NO20035683A NO20035683A NO20035683D0 NO 20035683 D0 NO20035683 D0 NO 20035683D0 NO 20035683 A NO20035683 A NO 20035683A NO 20035683 A NO20035683 A NO 20035683A NO 20035683 D0 NO20035683 D0 NO 20035683D0
Authority
NO
Norway
Prior art keywords
prostate cancer
optical imaging
imaging
optical
prostate
Prior art date
Application number
NO20035683A
Other languages
English (en)
Inventor
Jo Klaveness
Edvin Johannesen
Helge Tolleshaug
Original Assignee
Amersham Health As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Health As filed Critical Amersham Health As
Priority to NO20035683A priority Critical patent/NO20035683D0/no
Publication of NO20035683D0 publication Critical patent/NO20035683D0/no
Priority to US10/582,842 priority patent/US20080044350A1/en
Priority to PCT/NO2004/000394 priority patent/WO2005058372A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20035683A 2003-12-18 2003-12-18 Optisk avbildning av prostatakreft NO20035683D0 (no)

Priority Applications (3)

Application Number Priority Date Filing Date Title
NO20035683A NO20035683D0 (no) 2003-12-18 2003-12-18 Optisk avbildning av prostatakreft
US10/582,842 US20080044350A1 (en) 2003-12-18 2004-12-17 Optical Imaging Contrast Agents for Imaging Lung Cancer
PCT/NO2004/000394 WO2005058372A1 (en) 2003-12-18 2004-12-17 Optical imaging contrast agents for imaging lung cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO20035683A NO20035683D0 (no) 2003-12-18 2003-12-18 Optisk avbildning av prostatakreft

Publications (1)

Publication Number Publication Date
NO20035683D0 true NO20035683D0 (no) 2003-12-18

Family

ID=31885173

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035683A NO20035683D0 (no) 2003-12-18 2003-12-18 Optisk avbildning av prostatakreft

Country Status (3)

Country Link
US (1) US20080044350A1 (no)
NO (1) NO20035683D0 (no)
WO (1) WO2005058372A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597878B2 (en) 2000-09-19 2009-10-06 Li-Cor, Inc. Optical fluorescent imaging
EP2076292A2 (en) * 2006-10-25 2009-07-08 Koninklijke Philips Electronics N.V. Contrast agents for detecting prostate cancer
EP2117605B1 (en) 2007-02-28 2012-09-26 Sanofi Imaging probes
DE102007028659A1 (de) * 2007-06-21 2008-12-24 Siemens Ag Diagnosesubstanz und Verfahren zur Diagnose von Prostataerkrankungen
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
US20100104513A1 (en) * 2008-10-28 2010-04-29 General Electric Company Method and system for dye assessment
CA2745961A1 (en) * 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
WO2010076334A2 (en) * 2008-12-31 2010-07-08 Centre Leon Berard Intraoperative diagnosis of primary tumors and secondary tumors or metastases
DE102010010666A1 (de) * 2010-03-01 2011-09-01 Sven Reske Diagnose und Therapie von Krebserkrankungen mittels Fettsäuren
US20140308342A1 (en) 2011-11-11 2014-10-16 Yale University Reprogramming urokinase into an antibody-recruiting anticancer agent
US10111969B2 (en) 2014-09-17 2018-10-30 Rigshospitalet uPAR targeting peptide for use in peroperative optical imaging of invasive cancer
CN111393503B (zh) * 2019-01-03 2022-05-13 北京京东方技术开发有限公司 一种类肽及其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0800831B9 (en) * 1995-01-30 2004-11-10 Daiichi Pure Chemicals Co., Ltd. Diagnostic marker
JP2000507577A (ja) * 1996-04-01 2000-06-20 エピックス メディカル，インコーポレイテッド 画像診断用の生物活性造影剤
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
ATE314097T1 (de) * 1996-10-28 2006-01-15 Amersham Health As Kontrastmittel
US6083486A (en) * 1998-05-14 2000-07-04 The General Hospital Corporation Intramolecularly-quenched near infrared fluorescent probes
US6652836B2 (en) * 1998-10-15 2003-11-25 Fluoroprobe, Inc. Method for viewing tumor tissue located within a body cavity
DE19917713A1 (de) * 1999-04-09 2000-10-19 Diagnostikforschung Inst Kurzkettige Peptid-Farbstoffkonjugate als Konstrastmittel für die optische Diagnostik
JP2002541482A (ja) * 1999-04-13 2002-12-03 ヴィレックス アクチェンゲゼルシャフト 診断及び治療のためのウロキナーゼレセプターに対する抗体の使用
US6217848B1 (en) * 1999-05-20 2001-04-17 Mallinckrodt Inc. Cyanine and indocyanine dye bioconjugates for biomedical applications
US7790144B2 (en) * 2000-01-18 2010-09-07 Mallinckrodt Inc. Receptor-avid exogenous optical contrast and therapeutic agents
EP1283728A2 (en) * 2000-05-23 2003-02-19 Amersham Health AS Contrast agents
CA2410887C (en) * 2000-06-02 2012-07-24 Bracco Research Usa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
CA2422803A1 (en) * 2000-08-07 2002-02-14 Vanderbilt University Detection of cox-2 activity and anandamide metabolites
US20030044353A1 (en) * 2001-01-05 2003-03-06 Ralph Weissleder Activatable imaging probes
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
US7344700B2 (en) * 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
WO2005002293A2 (en) * 2003-06-25 2005-01-06 Vanderbilt University Cox-2-targeted imaging agents
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
US7371364B2 (en) * 2003-08-15 2008-05-13 Board Of Regents, The University Of Texas System Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy
NO20034350D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av kolorektal kreft

Also Published As

Publication number Publication date
US20080044350A1 (en) 2008-02-21
WO2005058372A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
EP1575420A4 (en) PROSTATE CANCER-BIOMARKERS
DK3470535T3 (da) Forudsigelse af sandsynlighed for tilbagevenden af cancer
DK1948180T3 (da) Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
EP1977237A4 (en) PREDICTING THE FORECAST FOR COLORECTAL CARCINOMA
FI20030326A0 (fi) Datan syöttö
KR100695846B9 (ko) 암 치료
NO20053782D0 (no) Behandling av kreft med 2-deoksyglukose
DE602004019373D1 (de) Bilderzeugungsverfahren
DK1660041T3 (da) Ikke-polær fotosensibilisator til fotodynamisk terapi
NL1029762A1 (nl) Bereiding van gesubstitueerde chinazolinen.
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
DK1587837T3 (da) Epitopsekvenser til diagnose og behandling af prostatacancer
NO20035681D0 (no) Optisk avbildning av lungekreft
DE602004030576D1 (de) Optisches aufzeichnungsverfahren
NO20035683D0 (no) Optisk avbildning av prostatakreft
DE112005003698A5 (de) Erfassung optischer Strahlung
DE602004026172D1 (de) Optischer detektor der enzymaktivierung
DK1589678T3 (da) Optisk antenne
NO20034350D0 (no) Optisk avbilding av kolorektal kreft
EP1698911A4 (en) RADIATION DETECTOR
NO20054188D0 (no) Et arrangement av fagverksstag
DE10347306B4 (de) Schirmanbindung
EP1789064A4 (en) ENHANCED ANTICANCER TREATMENT
NO20035748D0 (no) Optisk avbildning av sårbar arteriosklerose